![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Amgen Secures FDA Approval for Parsabiv to Treat Secondary Hyperparathyroidism
Amgen Secures FDA Approval for Parsabiv to Treat Secondary Hyperparathyroidism
February 15, 2017
The FDA approved Amgen’s Parsabiv — the first drug designated to treat secondary hyperparathyroidism in more than a decade — after rejecting the candidate last summer.
The approval was based on two placebo-controlled Phase III studies that found Parsabiv showed a significant reduction in parathyroid hormone secretions. The drug met both the primary and secondary endpoints of the studies, Amgen said.
In August, the FDA refused to approve the drug, issuing a complete response letter to the company. Amgen did not release the contents of the rejection letter.
Upcoming Events
-
21Oct